Nephro Care India Limited IPO
Nephro Care India (NCIL), a leading healthcare provider in East India specializing in multiple medical disciplines, has submitted its draft red herring prospectus (DRHP) to NSE Emerge in preparation for an initial public offering (IPO). The IPO will involve the issuance of 4,584,000 new equity shares, each priced at Rs10.
Based in Kolkata, NCIL offers a wide range of clinical services, lifestyle solutions, and treatments for renal insufficiency. In December 2023, the company successfully concluded its pre-IPO funding round, attracting notable investors such as former HDFC Ltd chairman Deepak Parekh, HDFC Securities chairman Bharat Shah, and Macleods Pharmaceuticals founder and MD Rajendra Agarwal.
According to the DRHP, NCIL plans to use the IPO proceeds to establish the 'Vivacity Multi Speciality Hospital' in Madhyamgram, Kolkata, West Bengal, and for general corporate purposes. This new hospital, a subsidiary of NCIL, will feature 100 inpatient beds, including a 30-bed Critical Care unit with ICU, HDU, RTU, and NICU facilities. Vivacity will offer comprehensive medical services, including cardiology, medical oncology, gastroenterology, gynecology, and advanced renal transplant procedures, with a focus on East India.
NCIL currently serves around 900 chronic kidney disease (CKD) patients monthly. Its flagship clinic in Salt Lake spans 5,352 sq. ft. and employs over five permanent physicians, ten visiting consultants, and a team of 70 skilled professionals. The company also operates satellite clinics in Salt Lake (HB 113) and Chandannagar, with plans to open three more in Alipurduar and Shyambazar in West Bengal, and Balasore in Odisha.
For the first nine months of FY 2023-24, NCIL reported a revenue of Rs.19.90 crore and a profit after tax (PAT) of Rs.3.4 crore, up from FY 2022-23's revenue of Rs.17.09 crore and PAT of Rs.1.94 crore.
Posted on : 28-06-2024